<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699723</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-35488</org_study_id>
    <secondary_id>NCI-2016-00180</secondary_id>
    <secondary_id>SKIN0033</secondary_id>
    <nct_id>NCT02699723</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer</brief_title>
  <official_title>Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean Yuh Tang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well arsenic trioxide and itraconazole work in treating&#xD;
      patients with basal cell cancer that has spread to other places in the body and usually&#xD;
      cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as arsenic&#xD;
      trioxide, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. Itraconazole may&#xD;
      help treat fungal infections in patients with basal cell cancer. Giving arsenic trioxide with&#xD;
      itraconazole may work better in treating basal cell cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the response of arsenic trioxide/itraconazole in patients with refractory&#xD;
      basal cell carcinoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if this treatment is associated with a reduction in Gli messenger ribonucleic&#xD;
      acid (mRNA) levels in tumor and/or normal skin biopsy samples, when compared to baseline&#xD;
      levels.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive arsenic trioxide orally (PO) and itraconazole PO daily for 50 days, followed&#xD;
      by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for&#xD;
      up to 6 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Logistics&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Gli levels</measure>
    <time_frame>Baseline to up to 1 month</time_frame>
    <description>Nonparametric methods (Wilcoxon sign rank test) will be used given then the continuous outcome and small sample size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
    <time_frame>At 3 months</time_frame>
    <description>Proportion of subjects with complete response, partial response, stable disease, or disease progression by RECIST criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Skin Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (arsenic trioxide, itraconazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (arsenic trioxide, itraconazole)</arm_group_label>
    <other_name>Arsenic (III) Oxide</other_name>
    <other_name>Arsenic Sesquioxide</other_name>
    <other_name>Arsenous Acid</other_name>
    <other_name>Arsenous Acid Anhydride</other_name>
    <other_name>Arsenous Oxide</other_name>
    <other_name>Trisenox</other_name>
    <other_name>White Arsenic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (arsenic trioxide, itraconazole)</arm_group_label>
    <other_name>Lozanoc</other_name>
    <other_name>Oriconazole</other_name>
    <other_name>R 51,211</other_name>
    <other_name>Sporanox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (arsenic trioxide, itraconazole)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Basal cell carcinoma (BCC)&#xD;
&#xD;
          -  Patients ineligible for curative locoregional treatment and have either progressed on,&#xD;
             did not tolerate, unwilling to try or ineligible for investigational smoothened&#xD;
             antagonist such as Erivedge or Odomzo&#xD;
&#xD;
          -  Life expectancy estimate &gt; 3 months&#xD;
&#xD;
          -  Performance status Eastern Cooperative Oncology Group (ECOG) 0 to 2&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =&lt;&#xD;
             2.5 X institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.9 mg/dL&#xD;
&#xD;
          -  Corrected QT (QTC) by 12 lead electrocardiography (EKG) &lt; 450 msecs&#xD;
&#xD;
          -  Serum potassium, magnesium and calcium levels which fall within normal limits or&#xD;
             levels outside the normal range determined not to be clinically significant by the&#xD;
             principal investigator (PI)&#xD;
&#xD;
          -  Serum prothrombin time, international normalized ratio (INR) and partial&#xD;
             thromboplastin times which fall within normal limits or levels outside the normal&#xD;
             range determined not to be clinically significant by the PI&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Females and males of reproductive potential must use effective contraception during&#xD;
             and after treatment for 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent use of other investigational agents&#xD;
&#xD;
          -  Cardiac arrhythmias&#xD;
&#xD;
          -  Receiving potassium wasting diuretics or amphotericin must be noted to have&#xD;
             theoretically increased arrhythmia risks with arsenic trioxide (potassium wasting&#xD;
             diuretics or amphotericin are not excluded)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, liver disease, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, recurrent seizure history or psychiatric illness/social&#xD;
             situations that would limit compliance with treatment requirements&#xD;
&#xD;
          -  Currently taking systemic medications that would affect BCC tumors (oral retinoids) or&#xD;
             metabolism of itraconazole (anti convulsants and corticosteroids); itraconazole should&#xD;
             not be taken with cisapride (Propulsid), dofetilide (Tikosyn), oral midazolam&#xD;
             (Versed), nisoldipine (Sular), pimozide (Orap), quinidine (Quinaglute), triazolam&#xD;
             (Halcion), or levomethadyl (Orlaam), lovastatin (Mevacor), simvastatin (Zocor), or an&#xD;
             ergot medication such as dihydroergotamine (Migranal), ergometrine or ergonovine&#xD;
             (Ergotrate Maleate), ergotamine (Ergomar), or methylergometrine or methylergonovine&#xD;
             (Methergine)&#xD;
&#xD;
          -  History or current evidence of malabsorption or liver disease that would impair the&#xD;
             absorption of itraconazole&#xD;
&#xD;
          -  History or current evidence of hyperthyroidism that would increase metabolism of&#xD;
             itraconazole&#xD;
&#xD;
          -  Immunosuppressed patients (cancer, autoimmune disease) or patients taking&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Tang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jean Yuh Tang</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

